JP2008019273A - 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト - Google Patents
虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト Download PDFInfo
- Publication number
- JP2008019273A JP2008019273A JP2007258682A JP2007258682A JP2008019273A JP 2008019273 A JP2008019273 A JP 2008019273A JP 2007258682 A JP2007258682 A JP 2007258682A JP 2007258682 A JP2007258682 A JP 2007258682A JP 2008019273 A JP2008019273 A JP 2008019273A
- Authority
- JP
- Japan
- Prior art keywords
- renal
- renal failure
- kidney
- treatment
- ischemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC*CC(N(C*c(cc1)ccc1-c(cccc1)c1-c1nnn[n]1)C=CC(O)=O)O Chemical compound CC*CC(N(C*c(cc1)ccc1-c(cccc1)c1-c1nnn[n]1)C=CC(O)=O)O 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
次いで、2つの試験グループに対照物質(NaCl 0.9%、1ml/kg)または例えばバルサルタン(0.3mg/kg)などのAT1−レセプターアンタゴニストのいずれかを静脈内注射する。注射30分後、左腎臓を側腹部を切開してさらし、血管クランプを用いて全部の血管柄を60分間しばる。この誘導虚血の間、動物を浅い麻酔状態に保つ。直腸の温度を連続的に測定し、体温を外部の赤色光照射を用いた制御システムを介して一律37.8℃に調節する。虚血60分後、クランプを取り外し、対側の無傷腎臓を反対の側腹部の切開により除去する。
グループ1:急性試験(虚血3時間後までの腎機能の測定)
グループ2:慢性試験(虚血48時間後の腎機能の測定)
有効成分として例えば(S)−N−(1−カルボキシ−2−メチルプロップ−1−イル)−N−ペンタノイル−N−[2'(1H−テトラゾール−5−イル)ビフェニル−4−イル−メチル]アミンを含有する硬ゼラチンカプセル剤は、例えば下記のように調剤し得る:
組成物
(1)バルサルタン 80.0mg
(2)微結晶セルロース 110.0mg
(3)ポリビドンK30 45.2mg
(4)ラウリル硫酸ナトリウム 1.2mg
(5)クロスポビドン 26.0mg
(6)ステアリン酸マグネシウム 2.6mg
Claims (7)
- 虚血後腎不全の予防および処置並びに虚血腎臓の保護のための医薬組成物の製造のためのAT1−レセプターアンタゴニストまたは医薬的に許容されるその塩の使用。
- 慢性虚血後腎不全の予防および処置のための医薬組成物の製造のための請求項1に記載の使用。
- 急性虚血後腎不全の予防および処置のための医薬組成物の製造のための請求項1に記載の使用。
- 血管系または大動脈の手術後、例えば大きな心臓手術後の、対応する手術の間の腎臓の低潅流の場合、血管柄をしばることによる腎臓の意図的な虚血の場合、腎腫瘍手術、腎動脈手術、腎石手術、腎移植の場合における使用、または腎臓移植におけるドナーへの予防的な使用、腎毒性問題、細胞外容量枯渇、中程度の腎潅流並びに圧挫症候群により誘導された心不全または腎不全の処置に使用する医薬組成物の製造のための請求項1に記載の使用。
- 治療有効量のAT1−レセプターアンタゴニストまたは医薬的に許容されるその塩を含有する、虚血後腎不全の予防および処置並びに虚血腎臓の保護のための医薬組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH282595 | 1995-10-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9514668A Division JPH11513395A (ja) | 1995-10-06 | 1996-09-24 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011176948A Division JP2011256195A (ja) | 1995-10-06 | 2011-08-12 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008019273A true JP2008019273A (ja) | 2008-01-31 |
Family
ID=4242452
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9514668A Withdrawn JPH11513395A (ja) | 1995-10-06 | 1996-09-24 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
JP2007258682A Ceased JP2008019273A (ja) | 1995-10-06 | 2007-10-02 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
JP2011176948A Pending JP2011256195A (ja) | 1995-10-06 | 2011-08-12 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9514668A Withdrawn JPH11513395A (ja) | 1995-10-06 | 1996-09-24 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011176948A Pending JP2011256195A (ja) | 1995-10-06 | 2011-08-12 | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
Country Status (16)
Country | Link |
---|---|
US (1) | US6071931A (ja) |
EP (1) | EP0853477B1 (ja) |
JP (3) | JPH11513395A (ja) |
AT (1) | ATE225657T1 (ja) |
AU (1) | AU7213296A (ja) |
BR (1) | BR9611007A (ja) |
CA (1) | CA2232663C (ja) |
CY (1) | CY2428B1 (ja) |
DE (1) | DE69624253T2 (ja) |
DK (1) | DK0853477T3 (ja) |
ES (1) | ES2184892T3 (ja) |
MY (1) | MY119312A (ja) |
PT (1) | PT853477E (ja) |
TW (1) | TW445147B (ja) |
WO (1) | WO1997013513A1 (ja) |
ZA (1) | ZA968378B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0855392A3 (de) | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
IT1295405B1 (it) * | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
PL193215B1 (pl) * | 1997-10-17 | 2007-01-31 | Eurogene Ltd | Zastosowanie lipofilnych inhibitorów układu renina-angiotensyna |
NZ587909A (en) | 1998-12-23 | 2012-05-25 | Novartis Ag | Process of making a compressed tablets containing valsartan and microcrystalline cellulose |
SE9902597D0 (sv) * | 1999-07-06 | 1999-07-06 | Astra Ab | New use |
WO2001097805A2 (en) * | 2000-06-22 | 2001-12-27 | Novartis Ag | Solid valsartan pharmaceutical compositions |
MY136446A (en) * | 2000-07-19 | 2008-10-31 | Novartis Ag | New salts of valsartan |
CA2420055C (en) * | 2000-08-25 | 2010-06-01 | Takeda Chemical Industries, Ltd. | Fibrinogen-lowering agent |
AU2003223637A1 (en) * | 2002-04-15 | 2003-11-03 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan) |
WO2005097109A1 (en) * | 2004-04-01 | 2005-10-20 | Daniel Batlle | Methods for achieving a protective ace2 expression level |
US10716749B2 (en) * | 2005-11-03 | 2020-07-21 | Palo Alto Investors | Methods and compositions for treating a renal disease condition in a subject |
JP2011063518A (ja) * | 2009-09-15 | 2011-03-31 | Tohoku Univ | Arb及び/又はグリタゾン系血糖降下物質を含有するoatp−r遺伝子発現増強組成物 |
RU2456615C1 (ru) * | 2011-03-25 | 2012-07-20 | Федеральное государственное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения и социального развития Российской Федерации | Способ профилактики отторжения трансплантата трупной почки |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0253310A2 (en) * | 1986-07-11 | 1988-01-20 | E.I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
EP0403159A2 (en) * | 1989-06-14 | 1990-12-19 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
EP0443983A1 (de) * | 1990-02-19 | 1991-08-28 | Ciba-Geigy Ag | Acylverbindungen |
WO1991014679A1 (fr) * | 1990-03-20 | 1991-10-03 | Sanofi | Derives heterocycliques n-substitues, leur preparation, les compostions pharmaceutiques en contenant |
JPH04261156A (ja) * | 1990-09-10 | 1992-09-17 | Abbott Lab | アンジオテンシンiiレセプター拮抗阻害剤 |
EP0504888A1 (en) * | 1991-03-21 | 1992-09-23 | G.D. Searle & Co. | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
WO1993020816A1 (en) * | 1992-04-13 | 1993-10-28 | Zeneca Limited | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
WO1994005289A1 (en) * | 1992-09-09 | 1994-03-17 | Vanderbilt University | Method and compositions for maintaining glomerular filtration rate while inhibition extracellular matrix accumulation |
EP0420237B1 (en) * | 1989-09-29 | 1996-03-06 | Eisai Co., Ltd. | Biphenylmethane derivative, the use of it and pharmacological compositions containing same |
EP0459136B1 (en) * | 1990-04-27 | 1996-12-27 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
EP0502314B1 (de) * | 1991-02-06 | 1998-05-20 | Dr. Karl Thomae GmbH | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
EP0514198B1 (en) * | 1991-05-16 | 1998-08-05 | Glaxo Group Limited | 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0629408A1 (en) * | 1993-06-16 | 1994-12-21 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Combination of angiotensin converting enzyme inhibitors and AII antagonists |
-
1996
- 1996-09-24 US US09/051,345 patent/US6071931A/en not_active Expired - Lifetime
- 1996-09-24 DK DK96933369T patent/DK0853477T3/da active
- 1996-09-24 MY MYPI96003925A patent/MY119312A/en unknown
- 1996-09-24 DE DE69624253T patent/DE69624253T2/de not_active Expired - Lifetime
- 1996-09-24 EP EP96933369A patent/EP0853477B1/en not_active Expired - Lifetime
- 1996-09-24 ES ES96933369T patent/ES2184892T3/es not_active Expired - Lifetime
- 1996-09-24 AT AT96933369T patent/ATE225657T1/de active
- 1996-09-24 PT PT96933369T patent/PT853477E/pt unknown
- 1996-09-24 WO PCT/EP1996/004162 patent/WO1997013513A1/en active IP Right Grant
- 1996-09-24 BR BR9611007A patent/BR9611007A/pt not_active Application Discontinuation
- 1996-09-24 JP JP9514668A patent/JPH11513395A/ja not_active Withdrawn
- 1996-09-24 CA CA002232663A patent/CA2232663C/en not_active Expired - Fee Related
- 1996-09-24 AU AU72132/96A patent/AU7213296A/en not_active Abandoned
- 1996-09-25 TW TW085111691A patent/TW445147B/zh not_active IP Right Cessation
- 1996-10-04 ZA ZA968378A patent/ZA968378B/xx unknown
-
2004
- 2004-02-27 CY CY0400015A patent/CY2428B1/xx unknown
-
2007
- 2007-10-02 JP JP2007258682A patent/JP2008019273A/ja not_active Ceased
-
2011
- 2011-08-12 JP JP2011176948A patent/JP2011256195A/ja active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0253310A2 (en) * | 1986-07-11 | 1988-01-20 | E.I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
EP0403159A2 (en) * | 1989-06-14 | 1990-12-19 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
EP0420237B1 (en) * | 1989-09-29 | 1996-03-06 | Eisai Co., Ltd. | Biphenylmethane derivative, the use of it and pharmacological compositions containing same |
EP0443983A1 (de) * | 1990-02-19 | 1991-08-28 | Ciba-Geigy Ag | Acylverbindungen |
WO1991014679A1 (fr) * | 1990-03-20 | 1991-10-03 | Sanofi | Derives heterocycliques n-substitues, leur preparation, les compostions pharmaceutiques en contenant |
EP0459136B1 (en) * | 1990-04-27 | 1996-12-27 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
JPH04261156A (ja) * | 1990-09-10 | 1992-09-17 | Abbott Lab | アンジオテンシンiiレセプター拮抗阻害剤 |
EP0502314B1 (de) * | 1991-02-06 | 1998-05-20 | Dr. Karl Thomae GmbH | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
EP0504888A1 (en) * | 1991-03-21 | 1992-09-23 | G.D. Searle & Co. | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
EP0514198B1 (en) * | 1991-05-16 | 1998-08-05 | Glaxo Group Limited | 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group |
WO1993020816A1 (en) * | 1992-04-13 | 1993-10-28 | Zeneca Limited | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
WO1994005289A1 (en) * | 1992-09-09 | 1994-03-17 | Vanderbilt University | Method and compositions for maintaining glomerular filtration rate while inhibition extracellular matrix accumulation |
Also Published As
Publication number | Publication date |
---|---|
ZA968378B (en) | 1997-04-07 |
DE69624253D1 (de) | 2002-11-14 |
WO1997013513A1 (en) | 1997-04-17 |
EP0853477A1 (en) | 1998-07-22 |
CA2232663C (en) | 2008-04-08 |
CA2232663A1 (en) | 1997-04-17 |
US6071931A (en) | 2000-06-06 |
CY2428B1 (en) | 2004-11-12 |
BR9611007A (pt) | 1999-07-13 |
MY119312A (en) | 2005-05-31 |
AU7213296A (en) | 1997-04-30 |
PT853477E (pt) | 2003-01-31 |
ATE225657T1 (de) | 2002-10-15 |
JPH11513395A (ja) | 1999-11-16 |
DK0853477T3 (da) | 2003-02-10 |
JP2011256195A (ja) | 2011-12-22 |
DE69624253T2 (de) | 2003-08-07 |
ES2184892T3 (es) | 2003-04-16 |
EP0853477B1 (en) | 2002-10-09 |
TW445147B (en) | 2001-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008019273A (ja) | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト | |
RU2298418C2 (ru) | Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза) | |
CZ304359B6 (cs) | Farmaceutická kombinační kompozice | |
SG188238A1 (en) | Combination therapy for treating hcv infection | |
MX2011000511A (es) | Uso de derivados de pirimidil-amino-benzamida para el tratamiento de fibrosis. | |
EP1755594A1 (en) | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
RU2298405C2 (ru) | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда | |
SK15452001A3 (sk) | Farmaceutický prípravok na predchádzanie, liečenie alebo inhibovanie vývoja jednoduchej retinopatie alebo predproliferačnej retinopatie | |
JP4836388B2 (ja) | eNOS発現に起因する疾患の予防または治療薬 | |
JP2009102399A (ja) | 利尿機能および腎機能を回復するためのアデノシンa1レセプターアンタゴニスト含有組成物および方法 | |
EP2157089A1 (en) | The therapeutic uses of imidazol-5-carboxylic acid derivatives | |
US20020042436A1 (en) | Use of angiotensin II receptor antagonists for treating acute myocardial infarction | |
US6174917B1 (en) | Method of treating liver disease and like indications with vasodilating agents | |
CN104220062B (zh) | (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合 | |
CN103037861A (zh) | 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途 | |
Quadri et al. | Recent advances in antihypertensive therapy | |
JPH05194217A (ja) | 抗高血圧組み合わせ医薬 | |
IE59308B1 (en) | A pharmaceutical composition for the treatment of high blood pressure | |
US20090118334A1 (en) | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker | |
JP2012254975A (ja) | Ace阻害剤とl−アルギニンを含有する医薬組成物 | |
CN117599062A (zh) | 一种辅助改善记忆、预防或治疗阿尔茨海默病的组合物 | |
JPWO2003061700A1 (ja) | 慢性腎疾患治療薬 | |
JPH09118622A (ja) | 血圧降下剤 | |
AU2005209657A1 (en) | Combination of at least two compounds selected from an AT1-Receptor antagonist or an ACE inhibitor or a HMG-CO-A reductase inhibitor group |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100921 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110322 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110812 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111005 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111025 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20120228 |